Combination of glucosamine improved therapeutic effect of low-dose cyclosporin A in patients with atopic dermatitis: A pilot study

Journal of Dermatology

Volumn 40, Issue 3, 2013, Pages 207-210

  Kwon, Hyok Bu ^a   Ahn, Byung Jin ^a   Choi, Yunseok ^a   Jin, Sang Y ^a   Cheong, Kyung A ^a   Lee, Joongyub ^b   Lee, Ai Young ^a  

^a Dongguk University   (South Korea)

^b Seoul National University Hospital   (South Korea)

Author keywords

atopic dermatitis; combination; cyclosporin; glucosamine; SCORAD

Indexed keywords

CYCLOSPORIN A; GAMMA INTERFERON; GLUCOSAMINE; GLUCOSAMINE SULFATE; INTERLEUKIN 4; INTERLEUKIN 5;

ADOLESCENT; ADULT; ADVERSE DRUG REACTION; ARTICLE; ATOPIC DERMATITIS; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; LOW DRUG DOSE; MALE; PILOT STUDY; SIDE EFFECT; TREATMENT DURATION;

ADOLESCENT; ADULT; CROSS-OVER STUDIES; CYCLOSPORINE; DERMATITIS, ATOPIC; DRUG THERAPY, COMBINATION; FEMALE; GLUCOSAMINE; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-4; LEUKOCYTES, MONONUCLEAR; LINEAR MODELS; MALE; PILOT PROJECTS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84874451694     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/1346-8138.12003     Document Type: Article

References (26)

1. Thestrup-Pedersen K,. Clinical aspects of atopic dermatitis. Clin Exp Dermatol 2000; 25: 535-543.
2. Faulds D, Goa KL, Benfield P,. Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders. Drugs 1993; 45: 953-1040.
3. Hijnen DJ, ten Berge O, Timmer-de Mik L, Bruijnzeel-Koomen CA, de Bruin-Weller MS,. Efficacy and safety of long-term treatment with cyclosporin A for atopic dermatitis. J Eur Acad Dermatol Venereol 2007; 21: 85-89.
4. Ricci G, Dondi A, Patrizi A, Masi M,. Systemic therapy of atopic dermatitis in children. Drugs 2009; 69: 297-306.
5. Sepp N, Fritsch PO,. Can cyclosporin A induce permanent remission of atopic dermatitis? Br J Dermatol 1993; 128: 213-216.
6. Reginster JY, Deroisy R, Rovati LC, et al,. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001; 357: 251-256.
7. Towheed TE, Anastassiades T,. Glucosamine therapy for osteoarthritis: an update. J Rheumatol 2007; 34: 1787-1790.
8. Ma L, Rudert WA, Harnaha J, et al,. Immunosuppressive effects of glucosamine. J Biol Chem 2002; 277: 39343-39349.
9. Zhang GX, Yu S, Gran B, Rostami A,. Glucosamine abrogates the acute phase of experimental autoimmune encephalomyelitis by induction of Th2 response. J Immunol 2005; 175: 7202-7208.
10. Forchhammer L, Thorn M, Met O, Gad M, Weidner MS, Claesson MH,. Immunobiological effects of glucosamine in vitro. Scand J Immunol 2003; 58: 404-411.
11. Kim DS, Park KS, Jeong KC, Lee BI, Lee CH, Kim SY,. Glucosamine is an effective chemo-sensitizer via transglutaminase 2 inhibition. Cancer Lett 2009; 273: 243-249.
12. Kuo CT, Leiden JM,. Transcriptional regulation of T lymphocyte development and function. Annu Rev Immunol 1999; 17: 149-187.
13. Ballard DW,. Molecular mechanisms in lymphocyte activation and growth. Immunol Res 2001; 23: 157-166.
14. Kim CH, Cheong KA, Park CD, Lee AY,. Glucosamine improved atopic dermatitis-like skin lesions in NC/Nga mice by inhibition of Th2 cell development. Scand J Immunol 2011; 73: 536-545.
15. Kunz B, Oranje AP, Labreze L, Stalder JF, Ring J, Taieb A,. Clinical validation and guidelines for the SCORAD index: consensus report of the European Task Force on Atopic Dermatitis. Dermatology 1997; 195: 10-19.
16. Anderson JW, Nicolosi RJ, Borzelleca JF,. Glucosamine effects in human: a review of effects on glucose metabolism, side effects, safety considerations and efficacy. Food Chem Toxicol 2005; 43: 187-201.
17. Persiani S, Rotini R, Trisolino G, et al,. Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulphate at therapeutic dose. Osteoarthritis Cartilage 2007; 15: 764-772.
18. Persiani S, Roda E, Rovati LC, Locatelli M, Giacovelli G, Roda A,. Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man. Osteoarthritis Cartilage 2005; 13: 1041-1049.
19. Schmitt J, Schmitt N, Meurer M,. Cyclosporin in the treatment of patients with atopic eczema-a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2007; 21: 606-619.
20. Moyer TP, Post GR, Sterioff S, Anderson CF,. Cyclosporine nephrotoxicity is minimized by adjusting dosage on the basis of drug concentration in blood. Mayo Clin Proc 1988; 63: 241-247.
21. Poolsup N, Suthisisang C, Channark P, Kittikulsuth W,. Glucosamine long-term treatment and the progression of knee osteoarthritis: systematic review of randomized controlled trials. Ann Pharmacother 2005; 39: 1080-1087.
22. Hathcock JN, Shao A,. Risk assessment for glucosamine and chondroitin sulfate. Regul Toxicol Pharmacol 2007; 47: 78-83.
23. Bissett DL,. Glucosamine: an ingredient with skin and other benefits. J Cosmet Dermatol 2006; 5: 309-315.
24. Knudsen JF, Sokol GH,. Potential glucosamine-warfarin interaction resulting in increased international normalized ratio: case report and review of the literature and MedWatch database. Pharmacotherapy 2008; 28: 540-548.
25. Persiani S, Canciani L, Larger P, et al,. In vitro study of the inhibition and induction of human cytochromes P450 by crystalline glucosamine sulfate. Drug Metabol Drug Interact 2009; 24: 195-209.
26. Combalbert J, Fabre I, Fabre G, et al,. Metabolism of cyclosporin A. IV. Purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. Drug Metab Dispos 1989; 17: 197-207.